TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA

時価総額

$277.7億

PER

ジェネリック・バイオシミラー・革新的医薬品の製造販売の最大手。AJOVYやAUSTEDOなどの主力製品を展開。約500品目、1,400剤型のポートフォリオ。2024年にPivot to Growth戦略実行。米国・欧州・国際市場35カ国超。

概要財務

サマリーテーブルに戻る

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash and cash equivalents	1,248	1,096	2,879	1,038	2,226	6,946	988	963	1,782	1,975	2,177	2,165	2,801	3,226	3,300
Accounts Receivable, Net, Current	5,476	6,213	5,572	5,338	5,408	5,350	7,523	7,128	5,822	5,676	4,581	4,529	3,696	3,408	3,059
Inventories	3,866	5,012	5,502	5,053	4,371	3,966	4,954	4,924	4,731	4,422	4,403	3,818	3,833	4,021	3,007
Prepaid expenses	-	-	-	-	-	-	-	-	899	870	945	1,075	1,162	1,255	1,006
Other current assets	-	-	-	-	-	-	-	-	468	434	710	965	549	504	409
Assets held for sale	-	-	-	-	-	-	-	-	92	87	189	19	10	70	1,771
Total current assets	12,042	14,453	16,355	13,720	14,396	18,398	16,961	15,382	13,794	13,464	13,005	12,573	12,051	12,485	12,552
Deferred income taxes	-	-	-	-	-	-	-	-	-	-	695	596	1,453	1,812	1,799
Other non-current assets	138	142	1,338	1,696	1,569	2,616	1,235	932	731	591	538	515	441	470	462
Property, plant and equipment, net	4,357	5,947	6,315	6,635	6,535	6,544	8,073	7,673	6,868	6,436	6,296	5,982	5,739	5,750	4,581
Operating lease right-of-use assets	-	-	-	-	-	-	-	-	-	514	559	495	419	397	367
Identifiable intangible assets, net	-	-	-	-	-	-	-	-	14,005	11,232	8,923	7,466	6,270	5,387	4,418
Goodwill	15,232	18,293	18,856	18,981	18,408	19,025	44,409	28,414	24,917	24,846	20,624	20,040	17,633	17,177	15,147
Total assets	38,152	50,142	50,609	47,508	46,420	54,258	92,890	70,615	60,683	57,470	50,640	47,666	44,006	43,479	39,326
Debt, Current	1,432	3,749	3,006	1,804	1,761	1,585	3,276	3,646	2,216	2,345	3,188	1,426	2,109	1,672	1,781
Sales reserves and allowances	-	-	4,934	4,918	5,849	6,601	7,839	7,881	6,711	6,159	4,824	4,241	3,750	3,535	3,678
Accounts payables	-	-	-	-	-	-	-	-	-	-	1,756	1,686	1,887	2,602	2,203
Employee-related obligations	-	-	-	-	-	-	-	-	870	693	685	563	566	611	624
Accrued expenses	-	-	-	-	-	-	3,405	3,014	1,868	1,869	1,780	2,208	2,151	2,771	2,792
Other current liabilities	995	1,396	1,572	1,926	1,508	1,225	867	724	804	889	933	903	1,005	1,056	1,020
Liabilities held for sale	-	-	-	-	-	-	-	-	-	-	-	-	-	-	698
Total current liabilities	9,694	13,847	12,888	11,965	12,289	13,005	18,519	17,921	14,322	13,674	13,164	11,027	11,469	12,247	12,796
Deferred income taxes	-	-	-	-	-	-	-	-	-	-	964	784	548	606	483
Other Liabilities, Noncurrent	777	1,106	1,293	1,273	1,109	1,195	1,639	1,843	1,727	2,640	2,240	2,578	3,847	4,019	4,028
Senior notes and loans	4,097	10,236	11,712	10,387	8,566	8,383	32,524	28,829	26,700	24,562	22,731	21,617	19,103	18,161	16,002
Operating lease liabilities	-	-	-	-	-	-	-	-	-	435	479	416	349	320	296
Total long-term liabilities	6,456	13,952	14,854	12,907	10,776	11,326	39,378	33,949	30,567	28,733	26,414	25,395	23,846	23,106	20,809
Total liabilities	16,150	27,799	27,742	24,872	23,065	24,331	57,897	51,870	44,889	42,407	39,579	36,422	35,315	35,353	33,606
Redeemable non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	-	-	340
Common Stock, Value, Issued	49	50	50	50	50	52	54	54	56	56	57	57	57	57	58
Additional paid-in capital	13,246	13,374	13,474	13,628	14,121	17,757	23,409	23,479,000,000	27,210	27,312	27,443	27,561	27,688	27,807	27,764
Accumulated deficit	9,325	11,284	12,346	12,535	14,436	14,851	13,607	-3,803	-5,958	-6,956	-10,946	-10,529	-12,882	-13,534	-15,173
Accumulated other comprehensive loss	350	-589	-17	-91	-1,343	-1,955	-3,159	-1,853	-2,459	-2,312	-2,399	-2,683	-2,838	-2,697	-3,148
Treasury shares as of December 31, 2024 and December 31, 2023: 107 million and 106 million ordinary shares, respectively	1,023	1,924	3,085	3,557	3,951	4,227	4,194	4,149	4,142	4,128	4,128	4,128	4,128	4,128	4,128
Stockholders' equity attributable to Teva shareholders	22,002	22,343	22,867	22,636	23,355	29,927	34,993	18,745	15,794	15,063	11,061	11,244	8,691	8,126	5,380
Non-controlling interests	55	148	99	71	42	158	1,656	1,386	1,087	1,091	1,035	966	794	620	7
Total equity	22,002	22,343	22,867	22,636	23,355	29,927	34,993	18,745	15,794	15,063	11,061	11,244	8,691	8,126	5,380
Total liabilities, redeemable non-controlling interests and equity	38,152	50,142	50,609	47,508	46,420	54,258	92,890	70,615	60,683	57,470	50,640	47,666	44,006	43,479	39,326